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Xiang-Yu Zhao, Ying-Jun Chang, Xiao-Jun HuangPartially HLA-mismatched related, or HLA-haploidentical, donor stem cell transplantation (SCT) is a feasible
therapeutic option for advanced hematologic malignancy patients who lack an HLA-matched related or
unrelated donor. Natural killer (NK) cells, a major cell type of the innate immune system, express surface
receptors that regulate potent effector functions, such as cytolytic activity and the release of cytokines,
and play a central role in the inflammatory response and immunoregulation. Conflicting results have been
reported regarding the impact of NK cell alloreactivity on the outcome of haploidentical SCT in leukemic
patients. This review summarizes the heterogeneous clinical results and explains the underlying mechanisms
with respect to the reconstitution kinetics of NK cells and the interactions between NK cells and T cells.
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Family human leukocyte antigen (HLA)-
mismatched/haploidentical transplantation is a feasi-
ble therapeutic approach for patients with lethal
malignant hematologic diseases who lack an HLA-
matched donor [1]. HLA mismatches could trigger
donor versus recipient natural killer (NK) cell alloreac-
tivity [2,3]. Clinical observations reveal a potential
role for NK cell alloreactivity in reducing the risk
of relapse in acute myeloid leukemia (AML) after
HLA-haploidentical SCT, especially in the Perugia
Bone Marrow Transplant Centre [4-6]. Furthermore,
clinical investigations have demonstrated that
alloreactive NK cell infusions are helpful in improving
transplantation outcomes [7-9]. However, it is notable
that the clinical success of this strategy has not been
convincingly reproduced in every study. This might
be a result of patient selection and different kinetics of
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receptors, and delayed cytotoxic function recovery. In
recent years, we have successfully established a novel
conditioning protocol that includes antithymocyte
globulin followed by haploidentical hematopoietic
stem cell transplantation (HSCT) without in vitro
T cell depletion [10]. We have found that this protocol
can achieve outcomes comparable to those obtained
with HLA-matched transplantation [11]. We have
also investigated the correlations between alloreactive
NK cells and the transplantation outcomes of
patients undergoing unmanipulated blood and marrow
transplantation [12-16]. However, we have not been
able to prove the beneficial effect of alloreactive
NK cells in haploidentical unmanipulated blood and
marrow transplantation without T cell depletion in
vitro. Because of the conflicting results for alloreactive
NK cells with respect to transplantation outcomes,
more research is being focused on the reconstitution
kinetics of NK cells to identify the underlying
mechanism [12,15,17-24]. Based on currently pub-
lished data and the heterogeneous clinical results, this
review focuses on the underlying mechanisms with
respect to the reconstitution kinetics of NK cells.Conflicting Impact of NK Alloreactivity on
Transplantation Outcomes from Different
Haploidentical Models
NK cells can discriminate ‘‘self’’ from ‘‘nonself’’
through their inhibitory natural killer receptor
Biol Blood Marrow Transplant 17:1436-1442, 2011 1437Impact of Alloreactive NK Cells on Transplantation Outcomes(NKR) expression [25]. The existence of alloreactive
NK cells relies on the balance of the active and inhib-
itory signals between NK cells and their target cells.
In biologic study of NK cells, there are at least
three models that exist to define NK alloreactivity: a
mismatch between the donor and recipient killer im-
munoglobulin receptor (KIR) ligands (ligand-ligand
model) [4] as defined by Perugia’s group; recipients
lacking KIR ligands for donor inhibitory KIR recep-
tors (receptor-ligand model) [26,27]; or a mismatch
between the donor and recipient KIR genes (gene-
gene model) [28]. The Perugia Bone Marrow Trans-
plant Centre developed transplantation from HLA
haplotype-mismatched family donors to provide
a cure for more patients [4-6]. Their series study
using a KIR-ligand mismatch to define alloreactive
NK cells demonstrates that HLA mismatches trigger
donor versus recipient NK cell alloreactivity, which
improves engraftment, protects from graft-versus-host
disease (GVHD), and reduces relapse in AML
patients. Following these clinical investigations, the
beneficial roles of alloreactive NK cells were demon-
strated in a mouse model of transplantation [5], show-
ing that these cells can perform the following
functions: (1) ablate AML cells, (2) kill recipient T cells,
permitting a reduced toxicity conditioning regimen,
and (3) ablate the recipient dendritic cells (DCs) that
trigger GVHD, thus protecting the recipient from
GVHD. Based on the beneficial roles of alloreactive
NK cells, adoptive immunotherapy using NK cells
has led to advances in graft engineering. Miller and
colleagues [7] used haploidentical, related-donor
NK-cell infusions in a nontransplantation setting to
prove that haploidentical NK cell infusion is safe, that
the cells can persist and expand in vivo, and that this ap-
proach may have a role in the treatment of selected ma-
lignancies when used alone or as an adjunct to HSCT.
Passweg and colleagues [8] further demonstrated that
purified donor NK-lymphocyte infusion is technically
feasible and can consolidate engraftment after haploi-
dentical stem cell transplantation (SCT). Remarkably,
a pilot study conducted to determine the safety, feasibil-
ity, and engraftment of haploidenticalNKcell infusions
after an immunosuppressive regimen in 10 children
with AML at first complete remission (CR1) recently
showed that all patients had transient engraftment
for a median of 10 days with limited nonhematologic
toxicity and no evidence of GVHD. At a median
follow-up time of 964 days, all the patients remained
in remission. The 2-year event-free survival (EFS) esti-
mate was 100% [9]. Taken together, these results
suggest that alloreactive NK cells definitely provide
favorable transplantation outcomes.
However, various conflicting results still exist
between the role of alloreactive NK cells and clinical
haploidentical transplantation outcomes from differ-
ent centers. Nearly all haploidentical transplantationwithout in vitro T cell depletion failed to show the
same result as the Perugia Bone Marrow Transplant
Centre. Using the ligand-ligand model, Bishara and
colleagues [29] demonstrated that in haploidentical
mismatched stem cell allografts with partial T cell
depletion in vitro, potential NK alloreactivity in the
GVHD direction was associated with an increased
incidence of severe GVHD and reduced patient sur-
vival but not with nonengraftment or leukemia relapse.
Huang and colleagues [13] also demonstrated that KIR
ligandmismatch is a strong risk factor for acuteGVHD
(aGVHD), relapse, and decreases overall survival (OS)
under haploidentical unmanipulated blood and mar-
row transplantation.These results are directly contrary
to the findings of Perugia’s group. When using the
ligand-ligand model, Symons and colleagues [30] also
failed to demonstrate the positive effect of alloreactive
NK cells. However, defining alloreactiveNK cells with
the gene-genemodel improved survival with inhibitory
KIR gene mismatches. In addition, KIR haplotype B
donors were found in patients who underwent non-
myeloablative, HLA-haploidentical bone marrow
transplantation [30]. In contrast,Huang and colleagues
[16] also failed to find improved survival in alloreactive
NK cell donors undergoing haploidentical unmanipu-
lated blood and marrow transplantation when using
the ligand-ligand model or even the receptor-ligand
model to define the alloreactive NK cells. Differences
inGVHDprophylaxis and graft cellularitymay explain
these varied results. In Perugia’s haploidentical trans-
plant protocol, T cell depletion is vigorous with stem
cell inocula containing an average of 3  106 T cells/
kg, compared with an average of 1.5  108 T cells/kg
in our protocol. Furthermore, the significant adverse
effect of the KIR ligand mismatch on the ‘‘high’’ T
cell group and the lack of an effect on the ‘‘low’’ T
cell group in aGVHD also prove that T cell dose plays
an important role in the allograft [13] that might affect
NK cell function and KIR expression in vivo, as re-
ported in unrelated HSCT. Therefore, the available
data suggest that a benefit of NK cell alloreactivity
could be obtained if specific strategies of haploidentical
transplantation, including high stem cell doses, exten-
sive T cell depletion, and no postgrafting immune sup-
pression, are used.Similar Reconstitution Patterns of NK Cells
following Different Haploidentical Models
Following the above rules, including high stem cell
doses, extensive T cell depletion, and no postgrafting
immune suppression in haploidentical SCT, Nguyen
and colleagues [18] also failed to find the graft-
versus-leukemia (GVL) effect. These results were
obtained despite the mismatch in the KIR ligand in
the GVH direction in 8 of 10 patients. Therefore, as
they are the first cells to recover after autologous or
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transplantation, the subsequent immune reconstitu-
tion of NK cells remains a major concern. In addition,
the recovered NK cells would be more important with
a sustained effect on GVHD and GVL after the
transplantation. In a study by Ruggeri and colleagues
[4,6], NK cell activity was correlated with reduced
relapse and superior OS for myeloid malignancies.
This conclusion was based on the finding of an
increased frequency of alloreactive NK cells in
patients receiving transplants from donors possessing
an inhibitory KIR ligand that was absent in
the recipient. These high frequencies of donor NK
clones could kill the target cells of the recipient in 8
of the 14 recipients during the first 3 postengraftment
months. However, in a study by Nguyen and
colleagues [18], NK cells were blocked at an immature
state that was characterized by phenotypic features and
impaired functioning, which may affect transplantation
outcome. Similar to the results of Nguyen et al., nearly
all phenotypical studies of NK subsets found an imma-
ture phenotype of NK cells after transplantation
among the haploidentical transplantations regardless
of the presence of in vitro T cell depletion with
nonmyeloablative or myeloablative conditioning [6,12,
15,17-21,23,24,31,32]. The reconstitution of NK cells
was rapid but accompanied by skewing of cell subsets,
mainly toward CD56bright. Indeed, the significant
deficiency of ‘‘cytotoxic’’ CD56dim NK cells was detec-
table up to 3 months after transplantation. Despite
regulation by the phenotype, the function of
NK cells is also regulated by the balance of activating
and inhibitory signals transmitted by different cell
surface receptors. Therefore, the expression of
activating NKRs, such as NKP46, NKP44, NKP30,
and NKG2D, as well as inhibiting NKRs, such
as CD158a, CD158b, CD158e, and NKG2A, is
essential for NK cell activation. Overall expression
of inhibitory NKRs and activating NKRs was
reduced, whereas CD94/NKG2A expression was
increased. NKG2A recovery was inversely correlated
with CD158b recovery in the year following trans-
plantation. This altered phenotype, which includes
more CD56bright and less CD56dim NK cells, altered
CD94/NKG2A expression. Activating or inhibiting
NKR expression during early reconstitution showed
lower levels of in vitro NK cell cytotoxicity after
haploidentical transplantation [6,12,15,17-21,23,24,
31,32]. The blockade of CD94/NKG2A restored
lysis against the AML blasts expressing HLA-E, which
is the ligand for CD94/NKG2A [33]. However, these
studies reflect the overall NK cell phenotype and func-
tion rather than the phenotype of the individual allor-
eactive NK cells. In general, the degree of cytolytic
activity correlates with the size of the phenotypically
defined alloreactive NK cell subsets. For patients
undergoing haploidentical HSCT, the size of the‘‘alloreactive’’ NK cell population present in potential
donors (eg, the parents) may be important for optimal
donor selection. It is crucial to identify this population
in the recipient post-HSCT to assess whether and how
it is generated in the allogeneic environment of the
recipient and whether it persists over time.Does Individual ‘‘Alloreactive’’ NK Cell
Reconstitution Govern the Haploidentical
Transplantation Outcomes?
Alloreactive NK cells are characterized by the
expression of KIRs specific for the KIR-ligand mis-
match and by the lack of other inhibitory receptors
specific for the HLA-class I alleles of the patient
[23,24]. Thus, to assess NK alloreactivity in haplo-
HSCT, it is necessary to analyze donor and recipient
HLA-class I and donor KIR genotypes. In addition,
the phenotypic analysis of KIR and CD94/NKG2A
expressed by donor NK cells can further define the
size of the alloreactive NK subset. Finally, functional
assays, based on the ability to kill appropriate target
cells, provide precise information on the degree of
alloreactivity of given NK cell populations.
Using appropriate combinations of monoclonal
antibodies (mAb), multicolor flow cytometric analysis
could distinguish between certain activating and inhib-
itory NKRs, making it possible to identify different
groups of alloreactive NK cells. KIR2DL1 recognizes
HLA-C alleles that have C2 specificity (eg, Cw2,
Cw4), whereas it does not react with C11 cells
(eg, Cw1, Cw3). Accordingly, KIR2DL11 cells kill
C1/C1 but not C21 leukemias. KIR2DL2/3 recog-
nizes C1 alleles, and it can also bind with lower affinity
to C2. Therefore, C11 leukemias are resistant to
KIR2DL2/31 NK cells, whereas C2/C2 leukemias
are lysed only partially. KIR3DL11 recognizes HLA-B
and HLA-A alleles carrying the Bw4 supertypic speci-
ficity. Thus, Bw41 leukemic blasts are resistant to
KIR3DL11 NK cells, whereas Bw42 leukemias are
susceptible. The KIR2DS1 activating receptor recog-
nizes the C2 specificity.
Thus far, 2 studies have investigated the reconstitu-
tion kinetics of alloreactive NK cells after haplo-HSCT.
Vago and colleagues [23] analyzed the reconstitution
of alloreactive single-KIR NK cells after haploidenti-
cal CD341 selected HSCT for high-risk hematologic
malignancies. The final graft product contained a
median of 11.3  106 CD341 cells/kg, that is, it
was extensively T cell-depleted (median, 1.07104
CD31 cells/kg). Fifty-three patients received a fully
myeloablative conditioning regimen, including
antithymocyte globulin (ATG) Fresenius at a total
dose of 25 mg/kg. Three patients underwent a second
salvage HSCT after the rejection of the first trans-
plant; they received immune-modulating condition-
ing that included thymoglobulin (6 mg/kg total
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tion, patients did not receive any posttransplantation
pharmacologic GVHD prophylaxis. Mature receptor
reconstitution required at least 3 months. Alloreactive
donor NK cells are defined by the expression of a
single KIR but not the other KIRs or CD94:NKG2A,
whose ligand is missing in the patient. These alloreac-
tive donorNK cells have been cloned from the periph-
eral blood of patients in the first 3 to 4 months after
haploidentical HSCT but are difficult to isolate at
later time points. At this time point, the supposedly
alloreactive, single-KIR1 NK cells were not yet fully
functional. The frequency of these cells was highly
variable; it is independent of predicted NK alloreac-
tivity and below 1% in the 3 of 6 alloreactive patients
studied. The recovery of functional activity compara-
ble to donor levels in 5 analyses of patients studied
more than 2 years after HSCT suggests that acquisi-
tion of the effector function is eventually achieved
but is a slow process that lags behind the recovery of
phenotypic maturity. Therefore, it was easy to postu-
late that these alloreactive NK cells can hardly have
an antileukemia effect during early transplantation.
The impact on clinical outcome of NK alloreactivity
predicted by the ligand-ligand model was assessed in
a retrospective analysis of 56 haploidentical transplan-
tations performed for high-risk malignancies in this
study. In line with the delayed reconstitution of
alloreactive NK cells after haplo-HSCT, no clinical
benefit of predicted NK alloreactivity was observed
in the total cohort of 56 patients. Therefore, the
kinetics and limits of NK-cell differentiation from
purified haploidentical hematopoietic stem cells were
evaluated in vivo, and the findings suggest that NK
cell antileukemic potential could be best exploited
by the infusion of mature single-KIR1 NK cells
selected from an alloreactive donor.
Soon afterward, Pende and colleagues [24] ana-
lyzed donor-derived alloreactive NK cells in pediatric
patients with leukemia who were given haplo-HSCT.
Themedian number of CD341 cells and of CD31 cells
infused/kg of recipient body weight was 23  106
(range: 10.6-41.2) and 5  103 (range: 0.5-35), respec-
tively. All patients were given ATG before the allograft
to minimize the risk of graft failure. No patient was
given posttransplantation pharmacologic immune
suppression. This study showed that donor-derived
alloreactive NK cells are generated and can persist for
years in haplo-HSCT recipients. KIR2DL2/31 NK
cells can barely distinguish between C11 and C21
target cells, and their alloreactivity is, in most cases,
dependent on the coexpression of KIR2DS1, which
can directly recognize C2 alleles on leukemia cells.
Remarkably, among the C1-mismatched pairs, all
patients given haplo-HSCT from donors expressing
KIR2DS1 (ie, 4 of 8) are alive and in complete
remission, whereas fatal relapses occurred in 3 of4 recipients transplanted from donors lacking this acti-
vating KIR. This finding suggests the clinical relevance
of KIR2DS1-mediated recognition of leukemia. Fur-
thermore, in NK cells derived from C1/C2 or C1/C1
donors, activation via KIR2DS1 may also overcome
the KIR2DL2/3-mediated inhibition, resulting in effi-
cient lysis of C2/C2 leukemias. In addition, KIR2DS1
can overcome the CD94/NKG2A-mediated inhibi-
tion, again resulting in the killing of C2/C2 leukemias.
Thus, the expression of KIR2DS1 may result in
NK cells that are endowed with alloreactivity and allow
a more precise definition of the size of the alloreactive
NK cell subset.
Although both of these haploidentical transplanta-
tion models were CD341 selected and relied on T cell
depletion without immune suppression after haplo-
HSCT, the phenotype and function reconstitution
kinetics of the alloreactive NK cells were absolutely
different, and the cells therefore provided different
clinical benefits. Quantitative analyses should be per-
formed in other retrospective studies to identify the
number of alloreactive NK cells required for a relevant
clinical role, especially in haplo-HSCT without T cell
depletion in vitro.
Given the alloreactive NK cell phenotype and
functional reconstitution after haplo-HSCT, the ques-
tion arises as to why donor NK cells undergoing mat-
uration in the mismatched recipient can develop into
alloreactive NK cells that are capable of killing leuke-
mia cells, as they express KIRs that are not engaged by
the HLA-class I alleles of the patient. The solution to
this question will involve issues of NK education after
transplantation. The process of repertoire shaping
may thus be regulated by additional mechanisms to
limit the frequency of inappropriate cells by deletion
or by induction of inhibitory receptors that recognize
self-ligands.Does NK Cell Education/Licensing after
Transplantation Ultimately Occur in the Donor
or Recipient?
Duringmaturation,NKcells were shown to require
the recognition of self-major histocompatibility com-
plex (MHC) class I to acquire full functionality, a phe-
nomenon referred to as ‘‘licensing’’ or ‘‘education’’[34].
A few NK cells lacking MHC-specific inhibitory
receptors can also be generated, but they would remain
virtually anergic or hyporesponsive. Significant debate
exists over the proposed mechanisms by which NK
receptor expression coordinates with the acquisition
of function and titration of responsiveness [35-45].
It is considered that NK cell education must occur to
permit the acquisition of function. However, there
has been some controversy in the literature as to
whether licensing occurs in the donor or the
recipient. So far, there is no relative literature about
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The available literature describes experiments that
are in the field of basic research or following HLA-
matched or unrelated transplantation with T cell
depletion in vitro [34-45].
Thus far, 3 studies have investigated the education
or licensing of alloreactive NK cells after HLA-
matchedor unrelated-HSCTwith orwithoutT cell de-
pletion [37,40,45]. In T cell-depleted, HLA-matched,
KIR-mismatched bone marrow transplants (in which
not all donor-derived NK cells are inhibited by the re-
cipient HLA or educated by donor or recipient HLA),
the number of inhibitory KIR-HLA mismatches (ie,
missing inhibitory ligands in the recipient) correlates
with positive outcomes, including fewer leukemic re-
lapses and improved graft acceptance [40]. From 16 T
cell-depleted HSCT donor-recipient pairs, Hsu and
colleagues [40] show that unlicensed, donor-derived
NK cells in the bone marrow recipient (ie, NK cells ex-
pressing inhibitory KIR recognizing non-self HLA
class I ligands) express high levels of interferon (IFN)-
g ex vivo and are competent to kill target cells, indicat-
ing that they are activated effector cells. However,
donor-derivedNKcells that are licensed (expressing in-
hibitory KIR for self-HLA class I ligands) are hyperre-
sponsive early post-HSCT. Thus, it was suggested that
NK cells early in the posttransplantation phase do not
behave strictly according to the tenets of NK licensing,
where onlyNK cells expressing inhibitory KIR for self-
HLA class I molecules are functionally competent. In-
stead, these findings support the possibility that NK
cells become activated upon recognition of a lack of
class I ligand for any inhibitory KIR (missing ligand)
in the first 3 to 6months afterHSCT, restricting them-
selves gradually to a tolerized state in which they
become activated only upon recognition of a lack of
self-class I ligands (missing self). However, Malmberg
and colleagues [45] found no influence of HLA and
KIR genotypes on DFS in the T cell-replete SCT sett-
ing.Theseclinicaldataweresupportedbya longitudinal
functional evaluation of NK cell repertoires during the
first 6 months after transplantation, revealing that edu-
catedNKcells expressing inhibitoryKIRs for self-HLA
class I ligands responded better at all examined time
points than uneducated NK cells lacking self-specific
receptors. NK cells expressing non-self KIRs remained
tolerant at all time points during the first 6months after
transplantation,whichwas in direct contrast to thefind-
ings of Hsu and colleagues [40]. Meanwhile, Dulphy
and colleagues [37] investigated NK cell education
after KIR-ligand-matched or -mismatched unrelated
HSCT. In line with Malmberg and colleagues [45],
it was found that after KIR-ligand-matched HSCT,
the NK cell subset responsiveness hierarchy was
consistent with the HLA genotype. After KIR-ligand-
mismatchedHSCT, theNK cell education process du-
rably reiterates the responsiveness pattern determinedby theHLA ligands of the donor. This finding strongly,
albeit indirectly, supports a hematopoietic origin for the
cellular partner in NK cell education. In view of these
data, the question arises as to how donor NK cell pre-
cursors undergoing maturation in the mismatched re-
cipient can give rise to alloreactive NK cells (ie,
effector cells capable of killing leukemia cells). A good
explanation might be the infusion of ‘‘megadoses’’ of
CD34 cells that could provide a bonemarrow (BM)mi-
croenvironment that is predominantly of the donor
type.Under these conditions, theprocess ofNKcell ed-
ucation would be similar to that occurring in the donor
and would allow the generation of ‘‘licensed’’ alloreac-
tive NK cells. The reason for the different results in
NK licensing between Malmberg et al. [45] and Hsu
et al. [40] might be the presence of T cells in the graft
and the use of posttransplantation immunosuppressive
treatment in the work of Malmberg and colleagues
[45]. Further supporting this model is the observation
that tolerance is acquired afterHSCT in haploidentical
transplants with KIR ligand incompatibility.Do T Cells in the Allograft Delay NK Cell
Reconstitution during Haploidentical
Transplantation?
Recent studies indicate that adaptive immune cells,
such as dendritic or T cells, play a role in NK cell dif-
ferentiation and activation. Considering the diverse
reconstitution kinetics of alloreactive NK cells and
the different associations with clinical outcomes after
haplo-HSCT, some authors focus on the effect of
T cells onNK cell reconstitution after transplantation.
Cooley and colleagues [46] showed in unrelated bone
marrow transplantation with either unmanipulated or
T cell-depleted transplants that the presence of T cells
in the graft altered the clinical outcome. The presence
of T cells was correlated with increased GVHD and
decreased KIR expression. However, in the haplo-
HSCT without T cell depletion or with partial
T cell depletion, the effect of T cells onNK cell recon-
stitution was different. Nguyen and colleagues [18]
found that the NK cells generated after haploidentical
SCT were characterized by specific phenotypic fea-
tures and impaired functioning. Therefore, they ob-
served an absence of the GVL effect in 10 patients
with AML who received haplo-mismatched SCT, de-
spite the mismatched KIR ligand in the graft-versus-
host (GVH) direction for 8 of 10 patients. By using
2 groups of patients, 1 undergoing partial T cell deple-
tion (pTCD) and the other undergoing extensive
T cell depletion (eTCD), Nguyen (19) showed that the
persistence of mature donor T cells in the graft seems
to enhance NK differentiation after haploidentical
SCT. After a pTCD transplant, the newly generated
NK cells rapidly acquire phenotypes and functions
similar to those found in the donors, in contrast to
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which remain completely immature. Despite the
strong aGVHD reaction, pTCD patients with T cells
present during SCT had a better clinical outcome than
patients with eTCD transplants. In addition, the fre-
quency of CD31CD56bright and NKG2A1 NK cells
was much lower in pTCD than in eTCD patients after
transplantation. In addition, the level of cytotoxicity
against primary haplo-mismatched blasts was signifi-
cantly more pronounced after pTCD than eTCD
transplants. These findings strongly suggest that
mature donor T cells in the graft may play a key
role in NK cell differentiation in vivo after haplo-
HSCT. However, Huang and colleagues [15] found
that following unmanipulated HLA-haploidentical/
mismatched blood and marrow transplantation, the
doses of the T cell subgroups CD41 and CD81 were
inversely associated with CD158a andCD158e expres-
sion during the 2 months following transplantation.
Patients with grades II-IV of aGVHD or who received
‘‘high’’ doses of T cells (.1.37  108/kg) showed
delayed recovery of KIRs during the 2 months follow-
ing transplantation. However, the number of NK cells
and the reconstitution kinetics of the subsets are
similar to those reported by Nguyen and colleagues
[12,18]. When comparing these results with the
results demonstrated by Nguyen and colleagues,
which showed that 7 of 10 patients relapsed and 3 of
10 died, the clinical outcomes of the study by Huang
and colleagues [15] are encouraging. Only 3 patients
from a total of 43 relapsed, and 11 died of
transplantation-related complications after haploi-
dentical transplantation without in vitro T cell
depletion. Moreover, the early rapid recovery of circu-
lating CD56bright NK cells was correlated with better
survival in the study by Huang and colleagues [15].
However, the frequency of CD31CD56bright and
NKG2A1 NK cells was much lower in pTCD than
in eTCD patients after transplantation. In addition,
the cytotoxicity against primary haplo-mismatched
blasts was significantly more pronounced after
pTCD than after eTCD transplants in the report of
Nguyen et al. Considering the communication
among CD56bright NK cells, DC cells, and T cells
and the rapid T cell reconstitution in unmanipulated
HSCT compared with CD341 selected hematopoietic
stem cell transplantations (HSCTs) [47-49], we suggest
that CD56bright NK cells might play important
immunoregulatory roles after unmanipulated haplo-
HSCT if the T cell reconstitution is sufficient. This
would help the cytotoxic function recovery of CD56dim
after transplantation.
The effect of alloreactive NK cells undergoing dif-
ferent haplo-HSCT varies according to the different
effects of the conditioning regimen, different levels
of T cell depletion, whether immune suppression is
used after transplantation, the actual alloreactive NKcell reconstitution, and the interaction of the NK cells
with DCs. Further investigation of the interaction of
alloreactive NK cells with immune cells (NK, DC,
and T cells) after haplo-HSCT may help to reveal
the diverse effects of alloreactive NK cells undergoing
different haplo-HSCT.ACKNOWLEDGMENTS
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